New hope for ALK lung cancer: first human trial of AQUA07 begins
Disease control
Not yet recruiting
This early-stage trial tests a new oral drug called AQUA07, alone or with another drug (lorlatinib), in about 102 people with ALK-positive non-small cell lung cancer that has spread or cannot be removed. The main goals are to check safety, find the right dose, and see how the bod…
Phase: PHASE1 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC